Transannular C-H heteroarylation of amines provides rapid access to complex scaffolds that are otherwise difficult to synthesize. Wide adaptation of this emerging reaction for medicinal chemistry requires a broad understanding of substrate scope and more robust experimental conditions. In this article, we report a new ligand to promote the transannular reaction of a range of fused- and bridged-bicyclic secondary amines with a broad set of heteroarenes. The method was also successfully applied to the arylation of one spiro-bicyclic amine, a class of substrates that has not been studied in the context of transannular C-H activation reactions. The broad application of this transannular C-H heteroarylation methodology is currently hampered by the difficulty of removing the directing group. The development of a new directing group that is easier to remove will expand the utility of this reaction.

01 May 2012·Alcoholism: Clinical and Experimental ResearchQ3 · MEDICINE

Effects of the Triple Monoamine Uptake Inhibitor DOV 102,677 on Alcohol‐Motivated Responding and Antidepressant Activity in Alcohol‐Preferring (P) Rats

Q3 · MEDICINE

Article

Author: Skolnick, Phil ; June, Harry L. Sr. ; Basile, Anthony S. ; June, Harry L. Jr. ; Tonelli, Leonardo ; Krieter, Philip A. ; Warnock, Kaitlin T. ; Yang, Andrew R. S. T. ; Mallick, Nikhil ; Mamczarz, Jacek ; Yi, Heon S.

Background: Concurrent inhibitors of dopamine, norepinephrine, and serotonin uptake have been proposed as novel antidepressants. Given the high comorbidity between alcoholism and depression, we evaluated the activity of DOV 102,677 (DOV) on alcohol‐maintained responding and performance in the forced swim test (FST), a model of antidepressant (AD) activity, using alcohol‐preferring (P) rats.Methods: Following training to lever press for either alcohol (10% v/v) or sucrose (3, 2%, w/v) on a fixed‐ratio 4 (FR4) schedule, DOV (1.56 to 50 mg/kg; PO) was given 25 minutes or 24 hours prior to evaluation. The effects of DOV (12.5 to 50 mg/kg; PO) in the FST were evaluated 25 minutes posttreatment.Results: DOV (6.25 to 50 mg/kg) dose‐dependently reduced alcohol‐maintained responding by 59 to 88% at 25 minutes posttreatment, without significantly altering sucrose responding. The reduction in alcohol responding (44% at 50 mg/kg) was sustained for up to 120 hours after a single dose. Administration of a single dose of DOV (25, 50 mg/kg) 24 hours before testing suppressed alcohol responding for 48 hours by 59 to 62%. DOV (12.5 to 50 mg/kg) also dose‐dependently reduced immobility of P rats in the FST.Conclusions: DOV produces both prolonged and selective reductions of alcohol‐motivated behaviors in P rats. The elimination kinetics of DOV suggests that its long duration of action may be due to an active metabolite. DOV also produced robust AD‐like effects in P rats. We propose that DOV may be useful in treating comorbid alcoholism and depression in humans.

01 Sep 2011·Central Nervous System Agents in Medicinal Chemistry

An Activity Model for Novel Antidepressants that Interact with the Serotonin Transporter (SERT)

Article

Author: Kessar, Satinder V. ; Pissurlenkar, Raghuvir R. S. ; Kulkarni, Shrinivas K. ; Coutinho, Evans C. ; Dhir, Ashish

Dysfunction of serotoninergic neurotransmission is known to be involved in the pathophysiology of major depression. The molecules that enhance the level of serotonin either via blocking serotonin reuptake or through inhibition of its metabolism are effective antidepressants. With this as the basis, a group of new molecules that supposedly effect serotoninergic neurotransmission were designed and tested. The new molecular entities (NME-2, NME-5, NME-16 and NME- 24) are active in animal models of behavioral despair. In the present study, the binding of these new NMEs to the serotonin transporter protein (SERT) has been modeled and their activity correlated with the behavioral pattern observed in the mouse forced swim test (FST) model. The putative binding orientations of the NMEs have been identified by docking the molecules into the active site of the SERT. A 3D model of the SERT active site was constructed using comparative protein modeling principles with the X-ray structure of the leucine transporter (LeuT) as template. 3D-QSAR models based on the CoRIA formalism were generated from the experimental data and docking scores for eight novel SERT inhibitors. The CoRIA models highlight the salient features for effective binding of NMEs to the serotonin transporter and are also able to predict pKd values. Based on the significant correlation between the anti-immobility effect seen in the mouse FST study and the binding energies obtained from the docking study along with insights from the interaction patterns with the receptor obtained from the docking, the CoRIA models can be used to suggest structural modifications that can help in optimization of the SERT inhibition. Experimental evidence shows that the NMEs are highly efficacious and could be developed into potential antidepressants.

100 Deals associated with DOV-102677

External Link

KEGG	Wiki	ATC	Drug Bank
-	DOV-102677	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alcoholism	Phase 1	United States	Euthymics Bioscience, Inc.	-
Attention Deficit Disorder With Hyperactivity	Phase 1	-	Euthymics Bioscience, Inc.	-
Depressive Disorder, Major	Phase 1	United States	DOV Pharmaceutical, Inc.	-
Depressive Disorder, Major	Phase 1	-	Euthymics Bioscience, Inc.	-
Restless Legs Syndrome	Phase 1	-	Euthymics Bioscience, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis